Company intelligence / Profile preview

Sunshine Lake Pharma

Dongguan, Guangdong, Chinapharm.hec.cn ↗

Ownership: Private
Employees: ~1000
Development stage: Phase 1

Overview

Sunshine Lake has several approved products in China including antivirals for hepatitis C and is advancing novel biologics such as a GLP‑1/FGF21 dual agonist into global clinical development. The company’s robust pipeline covers anti-infectives, oncology therapeutics, and chronic metabolic disease treatments with multiple programs in mid-to-late stage trials.

Therapeutic areas: GastroenterologyCardiovascularMetabolic DisordersEndocrinologyOncologyInfectious Diseases
Modalities: Small moleculeFusion proteinSynthetic peptideHormoneBiosimilar
Industry: Pharma

Drug pipeline

37 assets

mitizodone

36 more assets in the full pipeline.

Request access →

Partnerships

Apollo Therapeutics

Beyond the preview

Go deeper on Sunshine Lake Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sunshine Lake Pharma.

Explore the full profile